Nov

Nov EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Nov (NOV) as of Nov 4, 2026 is 12.76. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 8.62 — a change of 48.02% (higher).

EV/EBITDA

12.76

YoY

48.02%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Nov is 2025 12.76 . EV/EBITDA (Enterprise Value to EBITDA) of Nov was 2024 8.62 . It decreases by 48.02% higher compared to the previous year.

The Nov EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
60.09 USD
Jan 1, 2019
-1.24 USD
Jan 1, 2020
-2.66 USD
Jan 1, 2021
-44.03 USD
Jan 1, 2022
29.03 USD
Jan 1, 2023
12.16 USD
Jan 1, 2024
8.62 USD
Jan 1, 2025
12.76 USD
The Nov EV/EBITDA history
YEAREV/EBITDAYoY
12.76+48.02%
8.62-29.11%
12.16-58.11%
29.03-165.94%
-44.03+1,553.84%
-2.66+115.30%
-1.24-102.06%
60.09-335.34%
-25.53+649.86%
-3.41-84.55%
-22.04-1,344.80%
1.77—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nov Stock analysis

What does Nov do? Nov Inc is a globally operating company that was founded in the USA in 1976. The company specializes in the development and manufacture of products in various fields, including pharmaceuticals, biotechnology, agrochemicals, and electronics. Nov Inc's business model is based on the research and development of new technologies and products. The company invests a significant portion of its resources in the research and development of new drugs and technologies. Nov Inc works closely with scientific organizations and universities to achieve this. The goal of Nov Inc is to develop products that have a positive impact on health, science, and the environment. The company aims to improve the quality of life for people worldwide by developing innovative products that meet the needs of its customers. Nov Inc is divided into several divisions. The main divisions are pharmaceuticals, biotechnology, diagnostics, crop protection, and electronics. In each of these divisions, the company produces products tailored to the needs of its customers. In the pharmaceutical field, Nov Inc develops and produces drugs for the treatment of various diseases such as cancer, diabetes, and cardiovascular diseases. Nov Inc's products are well-known worldwide and are taken by millions of patients every day. The company is proud to make a significant contribution to improving the health of people worldwide. In the biotechnology division, Nov Inc develops products for use in agriculture and environmental protection. This includes improved seed varieties that are more resistant to insects and diseases, thus reducing the use of pesticides. Nov Inc also produces biological pesticides that protect plants from pests while being non-toxic and environmentally friendly. In the diagnostics division, Nov Inc develops and produces tests for the diagnosis of infectious diseases and other medical conditions. These tests are important for the timely detection of diseases and enable early treatment. In the electronics division, Nov Inc develops and produces electronic devices and components. This includes semiconductors, sensors, and displays. These components are used in various industries, including telecommunications, automotive, and aerospace. In addition to the above-mentioned divisions, Nov Inc also offers other products, including food additives, colorants, fragrances, and chemicals for industrial use. Overall, Nov Inc has made a significant contribution to improving health, science, and the environment over the past decades. The company is globally recognized for its innovative products and technologies and will remain an important player in research and development in the future. Nov is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nov stock

EV/EBITDA (Enterprise Value to EBITDA) of Nov is 12.76 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Nov changed from 8.62 to 12.76, representing a 48.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Nov since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Nov with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Nov

All Key Metrics — Nov